Pentadeca Arginate (PDA)
A modified BPC-157 derivative engineered for oral bioavailability — and the compound everyone's asking about since FDA enforcement shut down injectable BPC-157 compounding. Here's what the evidence actually shows (and what it doesn't).
📋 On this page
What Is Pentadeca Arginate?
The BPC-157 derivative built to survive oral delivery — and avoid the FDA's crosshairs.
The Molecule
PDA is BPC-157 with an arginate salt modification — arginine residue added to the C-terminus to improve GI stability and intestinal permeability. The core 15-amino-acid sequence is preserved.
Oral by Design
BPC-157 survives gastric acid reasonably well, but absorption across intestinal epithelium is the bottleneck. The arginate modification is theorized to improve this — though head-to-head oral absorption data is lacking.
Regulatory Position
PDA is formulated as a dietary supplement ingredient — not a compounded drug. This sidesteps the FDA's 503A/503B bulk ingredient restrictions that banned injectable BPC-157 from compounders in early 2026.
Mechanism (Inherited)
BPC-157 works primarily through the NO-system, growth hormone receptor modulation, and VEGF upregulation. PDA is expected to share this mechanism — the modification targets delivery, not pharmacology.
Who Developed It
PDA was introduced by supplement companies responding to the FDA enforcement environment. It is not a novel academic discovery — it's a commercially-driven formulation innovation.
Current Status
Available as oral capsules from select supplement vendors. Not FDA-approved, not scheduled, not a controlled substance. Research-chemical / supplement gray market territory as of 2026.
Why PDA Is Trending in 2026
The FDA enforcement timeline that created the market for PDA.
PDA vs. Injectable BPC-157
Where PDA improves on BPC-157, where it falls short, and what's still unknown.
| Factor | Injectable BPC-157 | Pentadeca Arginate (PDA) |
|---|---|---|
| Core sequence | 15 amino acids (GEPPPGKPADDAGLV) | Same core sequence + arginate modification |
| Route | Subcutaneous or intramuscular injection | Oral capsule |
| Bioavailability (oral) | ~Low (acid-stable but poor epithelial absorption) | ~Improved (arginate theorized to aid absorption — unconfirmed) |
| Published human trials | None (animal-only literature) | None |
| Animal research base | 500+ studies (30+ years) | Minimal — extrapolated from BPC-157 |
| FDA legal status (US) | Restricted — Category 2 bulk substance | Supplement-friendly — not on restricted list |
| Ease of use | Requires reconstitution, cold storage, injection | Oral capsule — no needles or storage requirements |
| Systemic vs local effect | Both — injection site + systemic | Primarily systemic via oral absorption (GI-local effects plausible) |
| Long-term safety data | Extensive animal data, no human LT studies | No long-term data of any kind |
| Typical cost | Was $30–80/month from compounders (now largely unavailable) | $50–120/month from supplement vendors |
The Evidence — An Honest Assessment
What exists, what doesn't, and how to think about extrapolated data.
📚 Primary Research Base
BPC-157 Literature: The mechanistic claims behind PDA rest on the BPC-157 body of work, primarily from Dr. Predrag Sikiric's lab at the University of Zagreb (30+ years of animal research).
Key domains: tendon/ligament healing, muscle recovery, gut protection (IBD, NSAID gastroprotection), CNS neuroprotection, angiogenesis. See the full BPC-157 research breakdown for citations.
⚠️ No PubMed results exist for "Pentadeca Arginate" as a specific compound as of March 2026.
Dosing Guidelines
Community-derived dosing extrapolated from BPC-157 oral protocols. No clinical dosing studies exist.
Starting Dose
Once daily, on an empty stomach. Starting low allows assessment of individual response before escalating.
Common Dose
1 mg/day is the most frequently reported dose in community protocols — split AM/PM or single dose.
Higher Range
2 mg/day reported by some users for injury recovery. No evidence this is more effective — increased cost and unknown risk.
Cycle Length
Typical cycle lengths mirror BPC-157 protocols: 4–8 weeks for acute use, up to 12 weeks ongoing. No data on optimal duration.
Timing
Fasted state recommended — take 30–60 minutes before food. The theoretical absorption benefit of the arginate modification may be diminished when taken with a meal.
Form
Oral capsules — typically 500 mcg per capsule. No reconstitution needed. Store per manufacturer guidance (room temp or refrigerated depending on vendor).
Cycling
Most community protocols cycle rather than run continuously — 4–8 weeks on, 4 weeks off. This is precautionary given the complete absence of long-term safety data.
Safety Considerations
BPC-157 has an unusually favorable animal safety profile — but that's not the same as PDA safety data.
• Pregnant or breastfeeding individuals (no safety data whatsoever)
• Anyone under 18 — no data, not appropriate
• Anyone with hormone-sensitive conditions without physician guidance
• Anyone expecting clinical evidence before using — it doesn't exist
Who Is PDA For?
Realistic candidate assessment — not a sales pitch.
Former Injectable BPC-157 Users
If injectable BPC-157 worked for you and you're looking for a legal continued option, PDA is the most direct alternative. You're extrapolating from known personal response, which is more information than the general population has.
Injury Recovery / Tendon/Ligament
BPC-157's best-evidenced use case. PDA is a reasonable consideration for someone who can't access injectable BPC-157, understands the evidence gap, and has tried conventional options.
GI Healing Goals
Oral delivery may actually be advantageous for gut-targeted effects — the compound is present in the GI tract where BPC-157 is naturally found. IBD, leaky gut, gastric ulcer contexts.
Not a Good Fit
Anyone looking for evidence-backed clinical outcomes, anyone risk-averse about novel compounds, anyone with cancer history, or anyone expecting it to work identically to well-studied injectable BPC-157.
Key Takeaways
What we know. What we don't.
✅ What We Know
- PDA shares BPC-157's 15-amino-acid core sequence
- BPC-157 has 30+ years of favorable animal safety data
- BPC-157 shows consistent healing effects across multiple animal models
- PDA is not restricted by FDA's 503A/503B bulk compounding rules
- Oral delivery is genuinely more convenient and accessible than injection
- Arginate salt modifications are a known pharmaceutical strategy to aid absorption
- GI-targeted use may benefit from oral delivery specifically
⚠️ What We Don't Know
- Whether the arginate modification actually improves oral bioavailability in humans
- What PDA's actual pharmacokinetics look like
- Whether PDA delivers equivalent efficacy to injectable BPC-157
- Optimal dose — all current dosing is extrapolated
- Long-term safety profile
- Whether PDA has its own distinct safety concerns from the modification
- Any human clinical outcomes data whatsoever
🔗 Related Resources
Dig deeper into BPC-157, healing peptides, and the regulatory landscape.
🛒 Recommended Products
Products relevant to an oral peptide protocol.
Affiliate links help support HighPeptides at no extra cost to you.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →